It has even been suggested that there is a loop in which tumor cell production of 17β-estradiol via aromatase activates ERα, and NSCLC patient response to pembrolizumab can be predicted by determining 17β-estradiol/ERα status [159]. The gene discussed is CYP19A1; the disease is non-small cell lung carcinoma.